Author/Authors :
Tanaka، نويسنده , , Ruriko and Kimura، نويسنده , , Shinya and Ashihara، نويسنده , , Eishi and Yoshimura، نويسنده , , Mariko and Takahashi، نويسنده , , Naoto and Wakita، نويسنده , , Hisashi and Itoh، نويسنده , , Kuniaki and Nishiwaki، نويسنده , , Kaichi and Suzuki، نويسنده , , Kenshi and Nagao، نويسنده , , Rina and Yao، نويسنده , , Hisayuki and Hayashi، نويسنده , , Yoshihiro and Satake، نويسنده , , Sakiko and Hirai، نويسنده , , Hideyo and Sawada، نويسنده , , Ken-ichi and Ottmann، نويسنده , , Oliver G. and Melo، نويسنده , , Junia V. and Maekawa، نويسنده , , Taira، نويسنده ,
Abstract :
ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR–ABL+ leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100 μL of whole blood within 90 min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the mutation-biased PCR (MBP) was added to the QP method to increase sensitivity, resulting earlier detection of T315I mutation which was insensitive to any ABL TKIs. Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients.
Keywords :
Quenching probe , Mutation-biased PCR , Bcr–Abl , Mutation , leukemia
